A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia

Bibliography

• Novartis. Clozaril (clozapine). Revised December 2010. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/Clozaril.pdf [Last accessed 4 June 2011]
   Google Scholar
• Janssen. Risperdal (risperidone). Revised December 2010. Available from: http://www.risperdal.com/sites/default/files/shared/pi/risperdal.pdf [Last accessed 4 June 2011]
   Google Scholar
• Eli Lilly. Zyprexa (olanzapine). Revised December 2010. Available from: http://pi.lilly.com/us/zyprexa-pi.pdf [Last accessed 4 June 2011]
   Google Scholar
• AstraZeneca. Seroquel (quetiapine). Revised May 2011. Available from: http://www1.astrazeneca-us.com/pi/Seroquel.pdf [Last accessed 4 June 2011]
   Google Scholar
• AstraZeneca. Seroquel XR (quetiapine extended release). Revised May 2011. Available from: http://www1.astrazeneca-us.com/pi/seroquelxr.pdf [Last accessed 4 June 2011]
   Google Scholar
• Pfizer. Geodon (ziprasidone). Revised December 2010. Available from: http://www.pfizer.com/files/products/uspi_geodon.pdf [Last accessed 4 June 2011]
   Google Scholar
• Bristol-Myers Squibb. Abilify (aripiprazole). Revised February 2011. Available from: http://www.abilify.com/pdf/pi.aspx [Last accessed 4 June 2011]
   Google Scholar
• Janssen. Invega (paliperidone). Revised April 2011. Available from: http://janssencns.com/sites/default/files/pdf/invega/invega.pdf [Last accessed 4 June 2011]
   Google Scholar
• Novartis. Fanapt (iloperidone). Revised April 2011. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/fanapt.pdf [Last accessed 4 June 2011]
   Google Scholar
• Merck. Saphris (asenapine). Revised January 2011. Available from: http://www.spfiles.com/pisaphrisv1.pdf [Last accessed 4 June 2011]
   Google Scholar
• Sunovion. Latuda (lurasidone). Revised October 2010. Available from: http://www.latuda.com/LatudaPrescribingInformation.pdf [Last accessed 4 June 2011]
   Google Scholar
• Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother 2009;10:1917-28
   PubMed Web of Science ®Google Scholar
• Citrome L, Nasrallah HA. On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not. Expert Opin Pharmacother In press
   Web of Science ®Google Scholar
• US National Library of Medicine and National Institutes of Health. PubMed.gov. Available from: http://www.ncbi.nlm.nih.gov/pubmed/ [Last accessed 20 June 2011]
   Google Scholar
• The Cochrane Collaboration. The Cochrane Library. Available from: http://www.thecochranelibrary.com/view/0/index.html [Last accessed 20 June 2011]
   Google Scholar
• Geddes J. Meta-analysis in the assessment of treatment outcome. J Psychopharmacol 2006;20(4 Suppl):67-71
   PubMedGoogle Scholar
• Khoshdel A, Attia J, Carney SL. Basic concepts in meta-analysis: a primer for clinicians. Int J Clin Pract 2006;60:1287-94
   PubMed Web of Science ®Google Scholar
• Huf W, Kalcher K, Pail G, Meta-analysis: fact or fiction? How to interpret meta-analyses. World J Biol Psychiatry 2011;12:188-200
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Rennie D. Users' Guides to the Medical Literature: Essentials of Evidence-Based Clinical Practice. AMA Press; Chicago, IL: 2001. p. 7; Table 1A-1
   Google Scholar
• Lam RW, Kennedy SH. Using metaanalysis to evaluate evidence: practical tips and traps. Can J Psychiatry 2005;50:167-74
   PubMed Web of Science ®Google Scholar
• Edwards SJ, Clarke MJ, Wordsworth S, Indirect comparisons of treatments based on systematic reviews of randomised controlled trials. Int J Clin Pract 2009;63:841-54
   PubMed Web of Science ®Google Scholar
• Anzures-Cabrera J. Higgins, JPT. Graphical displays for meta-analysis: an overview with suggestions for practice. Res Synth Methods 2010;1:66-80
   PubMed Web of Science ®Google Scholar
• Jones D. Of medicine and meta-analysis. Nat Rev Drug Discov 2008;7:376-7
   Web of Science ®Google Scholar
• Citrome L. Systematic reviews: much ado about a lot. Int J Clin Pract 2009;63:832-3
   PubMed Web of Science ®Google Scholar
• DeMaria AN. Meta-analysis. J Am Coll Cardiol 2008;52:237-8
   PubMed Web of Science ®Google Scholar
• Nasrallah HA. Meta-analysis trends in schizophrenia over three decades. Schizophr Res 2009;108:1-2
   PubMed Web of Science ®Google Scholar
• The Cochrane Collaboration. Home page. Available from: http://www.cochrane.org/ [Last accessed 20 June 2011]
   Google Scholar
• Higgins JPT, Green S. editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from: http://www.cochrane-handbook.org/ [Last accessed 20 June 2011]
   Google Scholar
• Cochrane IMS. Review Manager 5.1. Available from: http://ims.cochrane.org/revman [Last accessed 20 June 2011]
   Google Scholar
• Delgado-Rodriguez M. Systematic reviews of meta-analyses: applications and limitations. J Epidemiol Community Health 2006;60:90-2
   PubMed Web of Science ®Google Scholar
• Asenjo Lobos C, Komossa K, Rummel-Kluge C, Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010;11:CD006633
   Google Scholar
• Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev 2009;3:CD006324
   Google Scholar
• Essali A, Al-Haj Haasan N, Li C, Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 2009;1:CD000059
   Google Scholar
• Wahlbeck K, Cheine M, Essali MA. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 2000;2:CD000059
   Google Scholar
• Tuunainen A, Wahlbeck K, Gilbody SM. Newer atypical antipsychotic medication versus clozapine for schizophrenia. Cochrane Database Syst Rev 2000;2:CD000966
   Google Scholar
• Taylor DM, Smith L. Augmentation of clozapine with a second antipsychotic – a meta-analysis of randomized, placebo-controlled studies. Acta Psychiatr Scand 2009;119:419-25
   PubMed Web of Science ®Google Scholar
• Barbui C, Signoretti A, Mule S, Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull 2009;35:458-68
   PubMed Web of Science ®Google Scholar
• Paton C, Whittington C, Barnes TR. Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis. J Clin Psychopharmacol 2007;27:198-204
   PubMed Web of Science ®Google Scholar
• Moncrieff J. Clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination. Br J Psychiatry 2003;183:161-6
   PubMed Web of Science ®Google Scholar
• Tuunainen A, Wahlbeck K, Gilbody S. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophr Res 2002;56:1-10
   PubMed Web of Science ®Google Scholar
• Wahlbeck K, Cheine M, Essali A, Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999;156:990-9
   PubMed Web of Science ®Google Scholar
• Komossa K, Rummel-Kluge C, Schwarz S, Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2011;1:CD006626
   Google Scholar
• Rattehalli RD, Jayaram MB, Smith M. Risperidone versus placebo for schizophrenia. Cochrane Database Syst Rev 2010;1:CD006918
   Google Scholar
• Li C, Xia J, Wang J. Risperidone dose for schizophrenia. Cochrane Database Syst Rev 2009;4:CD007474
   Google Scholar
• Jayaram MB, Hosalli P, Stroup S. Risperidone versus olanzapine for schizophrenia. Cochrane Database Syst Rev 2006;2:CD005237
   Google Scholar
• Jayaram MB, Hosalli P. Risperidone versus olanzapine for schizophrenia. Cochrane Database Syst Rev 2005;2:CD005237
   Google Scholar
• Hunter RH, Joy CB, Kennedy E, Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev 2003;2:CD000440
   Google Scholar
• Kennedy E, Song F, Hunter R, Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev 2000;2:CD000440
   Google Scholar
• Gilbody SM, Bagnall AM, Duggan L, Risperidone versus other atypical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev 2000;3:CD002306
   Google Scholar
• Ezewuzie N, Taylor D. Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia. J Psychopharmacol 2006;20:86-90
   PubMed Web of Science ®Google Scholar
• Davis JM, Chen N. Clinical profile of an atypical antipsychotic: risperidone. Schizophr Bull 2002;28:43-61
   PubMed Web of Science ®Google Scholar
• Glick ID, Lemmens P, Vester-Blokland E. Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents. Int Clin Psychopharmacol 2001;16:265-74
   PubMed Web of Science ®Google Scholar
• Aleman A, Kahn RS. Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials. Eur Neuropsychopharmacol 2001;11:289-93
   PubMed Web of Science ®Google Scholar
• Peuskens J, Van Baelen B, De Smedt C, Effects of risperidone on affective symptoms in patients with schizophrenia. Int Clin Psychopharmacol 2000;15:343-9
   PubMed Web of Science ®Google Scholar
• Davies A, Adena MA, Keks NA, Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety. Clin Ther 1998;20:58-71
   PubMed Web of Science ®Google Scholar
• Song F. Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials. J Psychopharmacol 1997;11:65-71
   PubMed Web of Science ®Google Scholar
• de Oliveira IR, Miranda-Scippa AM, de Sena EP, Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety. J Clin Pharm Ther 1996;21:349-58
   PubMed Web of Science ®Google Scholar
• Carman J, Peuskens J, Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: a metaanalysis. Int Clin Psychopharmacol 1995;10:207-13
   PubMed Web of Science ®Google Scholar
• Komossa K, Rummel-Kluge C, Hunger H, Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010;3:CD006654
   Google Scholar
• Duggan L, Fenton M, Rathbone J, Olanzapine for schizophrenia. Cochrane Database Syst Rev 2005;2:CD001359
   Google Scholar
• Stauffer VL, Sniadecki JL, Piezer KW, Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder. BMC Psychiatry 2010;10:89
   PubMed Web of Science ®Google Scholar
• Beasley CM Jr, Stauffer VL, Liu-Seifert H, All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis. J Clin Psychopharmacol 2007;27:252-8
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Liu-Seifert H, Adams DH, Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia. J Clin Psychopharmacol 2006;26:632-7
   PubMed Web of Science ®Google Scholar
• Santarlasci B, Messori A. Clinical trial response and dropout rates with olanzapine versus risperidone. Ann Pharmacother 2003;37:556-63
   PubMed Web of Science ®Google Scholar
• Davis JM, Chen N. The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. J Clin Psychiatry 2001;62:757-71
   PubMed Web of Science ®Google Scholar
• Beasley CM Jr, Tollefson GD, Tran PV. Efficacy of olanzapine: an overview of pivotal clinical trials. J Clin Psychiatry 1997;58(Suppl 10):7-12
   PubMedGoogle Scholar
• Komossa K, Rummel-Kluge C, Schmid F, Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010;1:CD006625
   Google Scholar
• Srisurapanont M, Maneeton B, Maneeton N. Quetiapine for schizophrenia. Cochrane Database Syst Rev 2004;2:CD000967
   Google Scholar
• Srisurapanont M, Disayavanish C, Taimkaew K. Quetiapine for schizophrenia. Cochrane Database Syst Rev 2000;3:CD000967
   Google Scholar
• Srisurapanont M, Disayavanish C, Taimkaew K. Quetiapine for schizophrenia. Cochrane Database Syst Rev 2000;2:CD000967
   Google Scholar
• Schulz SC, Thomson R, Brecher M. The efficacy of quetiapine vs haloperidol and placebo: a meta-analytic study of efficacy. Schizophr Res 2003;62:1-12
   PubMed Web of Science ®Google Scholar
• Komossa K, Rummel-Kluge C, Hunger H, Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009;4:CD006627
   Google Scholar
• Bagnall A, Lewis RA, Leitner ML. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database Syst Rev 2000;4:CD001945
   Google Scholar
• Bagnall A, Lewis RA, Leitner ML, Ziprasidone for schizophrenia and severe mental illness. Cochrane Database Syst Rev 2000;2:CD001945
   Google Scholar
• Komossa K, Rummel-Kluge C, Schmid F, Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009;4:CD006569
   Google Scholar
• Bhattacharjee J, El-Sayeh HG. Aripiprazole versus typicals for schizophrenia. Cochrane Database Syst Rev 2008;3:CD006617
   PubMedGoogle Scholar
• Bhattacharjee J, El-Sayeh HG. Aripiprazole versus typicals for schizophrenia. Cochrane Database Syst Rev 2008;1:CD006617
   Google Scholar
• El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev 2006;2:CD004578
   PubMedGoogle Scholar
• El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev 2004;2:CD004578
   Google Scholar
• Janicak PG, Glick ID, Marder SR, The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. J Clin Psychiatry 2009;70:25-35
   PubMed Web of Science ®Google Scholar
• Kane JM, Assuncao-Talbott S, Eudicone JM, The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: a pooled analysis of data from the pivotal trials. Schizophr Res 2008;105:208-15
   PubMed Web of Science ®Google Scholar
• Kane JM, Crandall DT, Marcus RN, Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. Schizophr Res 2007;95:143-50
   PubMed Web of Science ®Google Scholar
• El-Sayeh HG, Morganti C, Adams CE. Aripiprazole for schizophrenia. Systematic review. Br J Psychiatry 2006;189:102-8
   PubMed Web of Science ®Google Scholar
• Volavka J, Czobor P, Citrome L, Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies. J Clin Psychiatry 2005;66:1362-6
   PubMed Web of Science ®Google Scholar
• Nussbaum A, Stroup TS. Paliperidone for schizophrenia. Cochrane Database Syst Rev 2008;2:CD006369
   Google Scholar
• Kozma C, Dirani R, Canuso C, Change in employment status over 52 weeks in patients with schizophrenia: an observational study. Curr Med Res Opin 2011;27:327-33
   PubMed Web of Science ®Google Scholar
• Jones MP, Nicholl D, Trakas K. Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia. Int J Clin Pharmacol Ther 2010;48:383-99
   PubMed Web of Science ®Google Scholar
• Patrick DL, Burns T, Morosini P, Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three phase III trials of paliperidone extended-release tablets. Clin Ther 2010;32:275-92
   PubMed Web of Science ®Google Scholar
• Emsley R, Berwaerts J, Eerdekens M, Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. Int Clin Psychopharmacol 2008;23:343-56
   PubMed Web of Science ®Google Scholar
• Kane JM, Lauriello J, Laska E, Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol 2008;28(2 Suppl 1):S29-35
   PubMed Web of Science ®Google Scholar
• Marshall M, Rathbone J. Early intervention for psychosis. Cochrane Database Syst Rev 2011;6:CD004718
   Google Scholar
• Marshall M, Rathbone J. Early intervention for psychosis. Cochrane Database Syst Rev 2006;4:CD004718
   Google Scholar
• Marshall M, Lockwood A. Early intervention for psychosis. Cochrane Database Syst Rev 2003;2:CD004718
   Google Scholar
• Furtado VA, Srihari V. Atypical antipsychotics for people with both schizophrenia and depression. Cochrane Database Syst Rev 2008;1:CD005377
   Google Scholar
• Marriott RG, Neil W, Waddingham S. Antipsychotic medication for elderly people with schizophrenia. Cochrane Database Syst Rev 2006;1:CD005580
   Google Scholar
• Rummel C, Hamann J, Kissling W, New generation antipsychotics for first episode schizophrenia. Cochrane Database Syst Rev 2003;4:CD004410
   Google Scholar
• Leucht S, Corves C, Arbter D, Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373:31-41
   PubMed Web of Science ®Google Scholar
• Leucht S, Komossa K, Rummel-Kluge C, A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009;166:152-63
   PubMed Web of Science ®Google Scholar
• Leucht S, Arbter D, Engel RR, How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 2009;14:429-47
   PubMed Web of Science ®Google Scholar
• Correll CU, Rummel-Kluge C, Corves C, Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 2009;35:443-57
   PubMed Web of Science ®Google Scholar
• Rabinowitz J, Levine SZ, Barkai O, Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features. Schizophr Bull 2009;35:775-88
   PubMed Web of Science ®Google Scholar
• Martin JL, Perez V, Sacristan M, Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia. Eur Psychiatry 2006;21:11-20
   PubMed Web of Science ®Google Scholar
• Basu A, Meltzer HY, Dukic V. Estimating transitions between symptom severity states over time in schizophrenia: a Bayesian meta-analytic approach. Stat Med 2006;25:2886-910
   PubMed Web of Science ®Google Scholar
• Sherwood M, Thornton AE, Honer WG. A meta-analysis of profile and time-course of symptom change in acute schizophrenia treated with atypical antipsychotics. Int J Neuropsychopharmacol 2006;9:357-66
   PubMed Web of Science ®Google Scholar
• Kemmler G, Hummer M, Widschwendter C, Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry 2005;62:1305-12
   PubMed Web of Science ®Google Scholar
• Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004;24:192-208
   PubMed Web of Science ®Google Scholar
• Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-64
   PubMed Web of Science ®Google Scholar
• Leucht S, Barnes TR, Kissling W, Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003;160:1209-22
   PubMed Web of Science ®Google Scholar
• Leucht S, Wahlbeck K, Hamann J, New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003;361:1581-9
   PubMed Web of Science ®Google Scholar
• Pajonk FG, Holzbach R, Naber D. Comparing the efficacy of atypical antipsychotics in open uncontrolled versus double-blind controlled trials in schizophrenia. Psychopharmacology (Berl) 2002;162:29-36
   PubMed Web of Science ®Google Scholar
• Sauriol L, Laporta M, Edwardes MD, Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach. Clin Ther 2001;23:942-56
   PubMed Web of Science ®Google Scholar
• Woods SW, Stolar M, Sernyak MJ, Consistency of atypical antipsychotic superiority to placebo in recent clinical trials. Biol Psychiatry 2001;49:64-70
   PubMed Web of Science ®Google Scholar
• Wahlbeck K, Tuunainen A, Ahokas A, Dropout rates in randomised antipsychotic drug trials. Psychopharmacology (Berl) 2001;155:230-3
   PubMed Web of Science ®Google Scholar
• Chakos M, Lieberman J, Hoffman E, Effectiveness of second-generation antipsychotics in patients with treatment resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001;158:518-26
   PubMed Web of Science ®Google Scholar
• Geddes J, Freemantle N, Harrison P, Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371-6
   PubMed Web of Science ®Google Scholar
• Srisurapanont M, Maneeton N. Comparison of the efficacy and acceptability of atypical antipsychotic drugs: a meta-analysis of randomized, placebo-controlled trials. J Med Assoc Thai 1999;82:341-6
   PubMedGoogle Scholar
• Leucht S, Pitschel-Walz G, Abraham D, Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51-68
   PubMed Web of Science ®Google Scholar
• Riedel M, Schennach-Wolff R, Musil R, Neurocognition and its influencing factors in the treatment of schizophrenia-effects of aripiprazole, olanzapine, quetiapine and risperidone. Hum Psychopharmacol 2010;25:116-25
   PubMed Web of Science ®Google Scholar
• Thornton AE, Van Snellenberg JX, Sepehry AA, The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review. J Psychopharmacol 2006;20:335-46
   PubMed Web of Science ®Google Scholar
• Woodward ND, Purdon SE, Meltzer HY, A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005;8:457-72
   PubMed Web of Science ®Google Scholar
• Keefe RS, Silva SG, Perkins DO, The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999;25:201-22
   PubMed Web of Science ®Google Scholar
• Citrome L, Jaffe A, Levine J. Dosing of second-generation antipsychotic medication in a state hospital system. J Clin Psychopharmacol 2005;25:388-91
   PubMed Web of Science ®Google Scholar
• Davis JM, Chen N. Old versus new: weighing the evidence between the first- and second-generation antipsychotics. Eur Psychiatry 2005;20:7-14
   PubMed Web of Science ®Google Scholar
• Leucht S, Kissling W, Davis JM. Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med 2009;39:1591-602
   PubMed Web of Science ®Google Scholar
• Citrome L, Volavka J. Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. Harv Rev Psychiatry 2002;10:280-91
   PubMed Web of Science ®Google Scholar
• Citrome L, Jaffe A, Levine J. How dosing of ziprasidone in a state hospital system differs from product labeling. J Clin Psychiatry 2009;70:975-82
   PubMed Web of Science ®Google Scholar
• Citrome L, Jaffe A, Levine J, Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies. J Clin Psychiatry 2005;66:1512-16
   PubMed Web of Science ®Google Scholar
• Citrome L. Treatment-refractory schizophrenia: what is it and what has been done about it? Neuropsychiatry 2011; 1:325-47
   Google Scholar
• Citrome L, Stroup TS. Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians? Int J Clin Pract 2006;60:933-40
   PubMed Web of Science ®Google Scholar
• Citrome L. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic. Int J Clin Pract 2009;63:1237-48
   PubMed Web of Science ®Google Scholar
• Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract 2009;63:1762-84
   PubMed Web of Science ®Google Scholar
• Sparshatt A, Jones S, Taylor D. Quetiapine: dose–response relationship in schizophrenia. CNS Drugs 2008;22:49-68
   PubMedGoogle Scholar
• Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ, Risperidone augmentation of clozapine: a critical review. Eur Arch Psychiatry Clin Neurosci 2006;256:350-5
   PubMed Web of Science ®Google Scholar
• Zink M. Augmentation of olanzapine in treatment-resistant schizophrenia. J Psychiatry Neurosci 2005;30:409-15
   PubMed Web of Science ®Google Scholar
• Taylor DM, Duncan-McConnell D. Refractory schizophrenia and atypical antipsychotics. J Psychopharmacol 2000;14:409-18
   PubMed Web of Science ®Google Scholar
• Tandon R. Improvement without impairment: a review of clinical data for quetiapine in the treatment of schizophrenia. J Clin Psychopharmacol 2003;23(3 Suppl 1):S15-20
   PubMed Web of Science ®Google Scholar
• Citrome L, Yang R, Glue P, Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials. Schizophr Res 2009;111:39-45
   PubMed Web of Science ®Google Scholar
• Buckley PF. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials. Curr Med Res Opin 2004;20:1357-63
   PubMed Web of Science ®Google Scholar
• Elsevier. Embase Biomedical Answers. Available from: http://www.embase.com/ [Last accessed 20 June 2011]
   Google Scholar
• Szegedi A, Verweij P, Van Duijnhoven W, P03-341- Meta-analysis of the efficacy of asenapine for acute schizophrenia: comparisons with placebo and other atypical antipsychotics. Eur Psychiatry 2011;26(Suppl 1):1511
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. PLoS Med 2009;6:e1000097
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100
   PubMed Web of Science ®Google Scholar
• Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ 2010;340:c221
   PubMed Web of Science ®Google Scholar
• Stroup DF, Berlin JA, Morton SC, Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-12
   PubMed Web of Science ®Google Scholar
• Rummel-Kluge C, Komossa K, Schwarz S, Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010;123:225-33
   PubMed Web of Science ®Google Scholar
• Rummel-Kluge C, Komossa K, Schwarz S, Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull 2010; [Epub 2010 May 31]
   PubMed Web of Science ®Google Scholar
• Mauri MC, Volonteri LS, Colasanti A, Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 2007;46:359-88
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
   PubMed Web of Science ®Google Scholar
• Leucht C, Heres S, Kane JM, Oral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 2011;127:83-92
   Google Scholar
• Preda A, Faziola L. Asenapine versus other atypical antipsychotics for schizophrenia [Intervention Protocol]. Cochrane Database Syst Rev 2010;12:CD008902
   Google Scholar
• Remington G, Chue P, Stip E, The crossover approach to switching antipsychotics: what is the evidence? Schizophr Res 2005;76:267-72
   PubMed Web of Science ®Google Scholar
• Jacques TS, Sebire NJ. The impact of article titles on citation hits: an analysis of general and specialist medical journals. JRSM Short Rep 2010;1:2
   PubMedGoogle Scholar
• Demner-Fushman D, Hauser S, Thoma G. The role of title, metadata and abstract in identifying clinically relevant journal articles. AMIA Annu Symp Proc 2005;191-5
   PubMedGoogle Scholar